BCL7A is a mammalian SWI/SNF chr12 remodeling complex subunit with critical roles in transcriptional regulation and tumor suppression. As a recently identified BAF complex component absent from yeast orthologs 1, BCL7A interacts directly with nucleosome core particles through an arginine anchor motif that binds the nucleosomal acidic patch, facilitating chr12 remodeling 2. BCL7A functions as a tumor suppressor across multiple hematological malignancies; it is frequently lost through promoter hypermethylation and genomic mutations affecting 62% of multiple myeloma patients and is mutated in 19.6% of all human tumors 13. In acute myeloid leukemia, BCL7A loss-of-function promotes malignant progression and chemotherapy resistance, while BCL7A upregulation impedes cell growth, induces apoptosis, and enhances drug sensitivity through IRF7/HMGCS1 pathway regulation 4. In multiple myeloma, BCL7A loss permits IRF4 transcriptional activity, driving proliferation and survival 3. Beyond cancer, BCL7A mutations contribute to inherited cardiac disease, including left ventricular noncompaction and bicuspid aortic valve in combination with MIB1 variants 5. Neurologically, BCL7A is essential for motor coordination and Purkinje cell dendritic development 6. Cancer-associated BCL7A mutations impair nucleosome binding, rationalizing disease pathogenesis and highlighting BCL7A as a therapeutic target in hematological malignancies.